Cite
HARVARD Citation
Banna, G. et al. (2022). A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. Lung cancer. pp. 77-83. [Online].